Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials (Q45247023)

11 December 2017

Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials (English)

1 reference

11 December 2017

1 reference

1 reference

Jordan J

1

1 reference

11 December 2017

Scholze J

2

1 reference

11 December 2017

Matiba B

3

1 reference

11 December 2017

Wirth A

4

1 reference

11 December 2017

Hauner H

5

1 reference

11 December 2017

Sharma AM

6

1 reference

11 December 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

International Journal of Obesity

11 December 2017

1 reference

11 December 2017

29

1 reference

11 December 2017

5

1 reference

11 December 2017

509-516

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ijo.0802887

11 December 2017

0 references

cites work

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

Sibutramine produces dose-related weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

The discovery and status of sibutramine as an anti-obesity drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

Paradoxical effect of sibutramine on autonomic cardiovascular regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

Long-term weight loss with sibutramine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

Effect of Weight Loss without Salt Restriction on the Reduction of Blood Pressure in Overweight Hypertensive Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

The Obesity Epidemic Is a Worldwide Phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

7 January 2021

The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

7 January 2021

Relationship between the overflow of endogenous and radiolabelled noradrenaline from canine blood perfused gracilis muscle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

7 January 2021

Cl- secretion by cultured shark rectal gland cells. II. Effects of forskolin on cellular electrophysiology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

7 January 2021

Sympathetic activation in obese normotensive subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

7 January 2021

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

7 January 2021

A general parametric approach to the meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

7 January 2021

Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

7 January 2021

A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

7 January 2021

Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

7 January 2021

Adrenergic and reflex abnormalities in obesity-related hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

7 January 2021

Sibutramine and its cardiovascular profile

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802887

7 January 2021

Identifiers

DOI

10.1038/SJ.IJO.0802887

1 reference

Dimensions Publication ID

11 December 2017

0 references

1 reference